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Peptide nucleic acids (PNAs) are DNA-mimicking mol-
ecules in which the sugar-phosphate backbone is re-
placed by a pseudopeptide backbone composed of N-(2-
aminoethyl)glycine units. We determined whether
double-stranded molecules based on PNAs and PNA-
DNA-PNA (PDP) chimeras could be capable of stable
interactions with nuclear proteins belonging to the Sp1
transcription factor family and, therefore, could act as
decoy reagents able to inhibit molecular interactions
between Sp1 and DNA. Since the structure of PNA/PNA
hybrids is very different from that of the DNA/DNA dou-
ble helix, they could theoretically alter the molecular
structure of the double-stranded PNA-DNA-PNA chime-
ras, perturbing interactions with specific transcription
factors. We found that PNA-based hybrids do not inhibit
Sp1/DNA interactions. In contrast, hybrid molecules
based on PNA-DNA-PNA chimeras are very effective de-
coy molecules, encouraging further experiments fo-
cused on the possible use of these molecules for the
development of potential agents for a decoy approach in
gene therapy. In this respect, the finding that PDP-
based decoy molecules are more resistant than DNA/
DNA hybrids to enzymatic degradation appears to be of
great interest. Furthermore, their resistance can even
be improved after complexation with cationic liposomes
to which PDP/PDP chimeras are able to bind by virtue of
their internal DNA structure.
In vitro transfection of cis elements that decoy against nu-
clear factors leads to alteration of gene expression and was
recently proposed in molecular medicine as a novel tool for the
possible therapy of several disorders (1–12). One of the most
effective decoy approaches so far described involves nuclear
proteins belonging to the NF-B1 superfamily (7–9, 13–20).
Decoy molecules against NF-B inhibit the expression of
NF-B regulated genes (MHC complex genes, IL2 receptor ,
Igk, IL6,  opioid receptor, preprogalanin, adhesion molecule-1)
(20). More recently, dumbell DNA decoy elements against
NF-B were demonstrated to be active in inhibiting ex vivo
transcription driven by the long terminal repeat (LTR) of hu-
man immunodeficiency type-1 virus (HIV-1) (19). In addition to
proteins belonging to the NF-B superfamily, decoy molecules
for other target transcription factors, such as HNF-1, RFX1,
nuclear factor YB, E2F, cAMP-response element, and Sp1,
were found to be effective (1–6, 10–12, 21).
As to the molecular targets for the decoy approach, proteins
belonging to the Sp1 family are of great interest since these
transcription factors are involved in the regulation of the ex-
pression of several genes relevant to human pathologies, in-
cluding those encoding vascular endothelial growth factor,
plasminogen-activator inhibitor type-1 (PAI-1), COL1A2,
urokinase-type plasminogen activator (uPA), and uPA receptor
(3, 21–25). Sp1 binding sites are also present in the HIV-1 LTR
(26). Thus, the development of experimental approaches based
on Sp1 decoys to modulate the transcription of Sp1-dependent
genes appears to be of great interest (3).
Recently, Ishibashi et al. (3) demonstrated that transfection
of oligodeoxynucleotides (ODNs) carrying the consensus se-
quence for Sp1 binding (Sp1 decoy ODNs) was able to inhibit
the tumor necrosis factor--mediated expression of both vascu-
lar endothelial growth factor and transforming growth factor
1. These results are appealing since it is well known that the
expression of these genes is an important aspect in growth and
metastasis of solid tumors. In addition, it was found that the in
vitro invasiveness, synthesis of mRNA for uPA, and cell prolif-
eration were also inhibited by the transfection of Sp1 decoy
ODNs, suggesting that Sp1 decoy strategy could be effective for
regulating tumor growth by reducing in cancer cell (a) angio-
genic growth factor expression, (b) proliferation, and (c) inva-
siveness. In another report, Verrecchia et al. (21) found that
decoy Sp1-binding ODNs inhibited COL1A2 promoter activity
both in cultured fibroblasts and in vivo, in the skin of trans-
genic mice, which have integrated a mouse COL1A2 promoter/
luciferase reporter gene construct, indicating that targeting
Sp1 efficiently blocks extracellular matrix gene expression, and
suggest that such an approach may represent an interesting
therapeutic alternative toward the treatment of fibrotic
disorders.
The activity of decoy molecules carrying Sp1 binding sites
was also studied by Motojima et al. (22) and by Hata et al. (25).
Motojima et al. (22) demonstrated that Sp1 decoys are able to
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inhibit angiotensin II-induced up-regulation of PAI-1 gene ex-
pression in mesangial cells (22). Hata et al. (25) showed that
Sp1 decoys reduced expression of kinase domain receptor, a
high affinity, endothelial cell-specific, autophosphorylating ty-
rosine kinase receptor for vascular endothelial growth factor.
This transcriptionally regulated receptor is a critical mediator
of endothelial cell growth and vascular development (25).
In a recent study, we have investigated the possible use of
peptide nucleic acids (PNAs) (27–30) as alternative reagents in
experiments aimed at the control of gene expression involving
the decoy approach (20, 31). In PNAs, the pseudopeptide back-
bone is composed of N-(2-aminoethyl)glycine units (27). PNAs
hybridize with high affinity to complementary sequences of
single-stranded RNA and DNA, forming Watson-Crick double
helices (28, 29), are resistant to both nucleases and proteases
(30, 32), and were found to be excellent candidates for anti-
sense and antigene therapies (33–35). We demonstrated that
NF-B p52 is able to bind to both DNA/DNA and DNA/PNA
hybrids mimicking the NF-B target sites present in the HIV-1
LTR. On the contrary, low binding of NF-B p52 to PNA/PNA
hybrids was found (20). We have also reported a conformational
study to explain these binding data using a molecular dynam-
ics approach. These data have underlined that the loss of
charged phosphate groups and the different shape of the helix
in PNA/DNA and PNA/PNA hybrids drastically reduce binding
efficiency to NF-B transcription factor (31).
More recently, PNA-DNA chimeras have been described as
reagents of great interest in gene therapy. PNA-DNA chimeras
are PNA-DNA (30, 36–39) covalently bonded hybrids and were
designed on the one hand to improve the poor cellular uptake
and solubility of PNAs and on the other hand to exhibit biolog-
ical properties typical of DNA, such as the ability to stimulate
RNaseH activity and to act as substrate for cellular enzymes
(for instance DNA polymerases). Finally, PNA-DNA chimeras
in which the PNA part is attached to 3- or 5-ends of the DNA
are expected to be particularly stable against degradation by
3- and/or 5-exonucleases, which represent the major type of
oligonucleotide degrading enzymes found in serum (30).
In the present report, we determined whether PNA/PNA and
PNA/DNA hybrid could act as decoy molecules for transcription
factor Sp1. Furthermore, we investigated binding to Sp1 tran-
scription factor(s) and biological activity of PNA-DNA-PNA
chimeras mimicking Sp1 binding sites.
MATERIALS AND METHODS
Synthetic Oligonucleotides and Peptide Nucleic Acids—The synthetic
oligonucleotides used in this study were purchased from Amersham
Biosciences. HPLC-purified PNAs were purchased from ISOGEN Bio-
sciences (Maarssen, the Netherlands).
PNA-DNA-PNA Oligomer Assembly—Chimera synthesis proceeded
by sequential elongation of the PNA fragment, to which DNA first and
then PNA were attached. Aminomethyl-polystiren-NH2 resin (loading
37 mol/g), resin functionalized with an hexamethylene bisacetamide
linker bound through an ester bond to a Gly, was used. The DNA part
of the chimera was prepared on an Amersham Biosciences Gene As-
sembler. Chain elongation was performed with 15 eq of methyl DNA
phosphoramidites using 5-(o-nitrophenyl)tetrazole (8 eq) as the activa-
tor. Standard DNA capping, washing, oxidation, and detritylation cy-
cles were used. Coupling yields were gauged spectrophotometrically
(254 nm) by the absorption of the released trityl cation after each
deprotection step. In the last DNA elongation step, cyanoethyl 5-amino-
5-deoxythymidine phosphoramidite was used (38, 39). The PNA part of
the chimera was prepared on a full automated PerSeptive Biosystems
Expedite 8900 Nucleic Acid synthesizer (PerSeptive Biosystems, Foster
City, CA) using standard (designed for 2-mol scale) PNA coupling
cycles and solutions. Fmoc (Bz, benzyl)/(iBu, isobutyl)-protected PNA
was used. To improve the coupling efficiency of the first PNA moiety, a
double coupling cycle was employed (40). Upon completion of the last
elongation cycle, the terminal Fmoc group was cleaved by piperidine
treatment, and the primary amine was acetylated. The methyl groups
were removed from the phosphate functions by treatment of the resin
with 0.25 ml of thiophenol in 0.5 ml of tetrahydrofuran and 0.5 ml of
triethylamine for 45 min. The resin was washed consecutively with
tetrahydrofuran, methanol, acetonitrile, and water (5  1 ml for each
solvent). The oligomers were cleaved from the support with concomitant
deprotection of the remaining protective groups by treatment with 0.1
M sodium hydroxide in water/dioxane (1/1, v/v, 1.5 ml) at 55 °C for 16 h.
The reaction mixtures were neutralized by the addition of acetic acid,
concentrated, and redissolved in 0.15 M ammonium bicarbonate. De-
salting was performed using a Sephadex G-25 (superfine, DNA grade)
gel filtration column with 0.15 M ammonium bicarbonate buffers. Sam-
ples were filtered and then purified by reverse-phase-HPLC on a Li-
Crosphere 100 RP-18 endcapped column (4 250 mm) on a Jasco HPLC
system. Gradient elution was performed at 40 °C, building up gradient
starting with buffer A (50 mM triethylammonium acetate in water) and
applying buffer B (50 mM triethylammonium acetate in acetonitrile/
water 1/1 v/v) with a flow rate of 1 ml/min. Matrix-assisted laser
desorption ionization time-of-flight (MALDI-TOF) analyses were per-
formed on all chimeras as follows: (a) 5842.6 (MH) and (b) 5602.0
(MH); (a) cag- *TGA GGC GTG GCCA -ggg-Gly and (b) ccc- *TGG
CCACGC CTCA -ctg-Gly.
Electrophoretic Mobility Shift Assay—The electrophoretic mobility
shift assay (41, 42) was performed using the double-stranded synthetic
oligonucleotides mimicking the Sp1 (nucleotide sequences are pre-
sented in Table I and in Fig.1). The DNA stretches of the target
molecules were 5-end-labeled using [-32P]ATP and T4 polynucleotide
kinase (MBI Fermentas, Milano, Italy) in the case of DNA/DNA, DNA/
PNA, and DNA/PDP hybrids. 32P-labeled PDP/PDP molecules were
obtained by nick translation, using low concentrations (0.1–0.01 units/
reaction) of DNase I and [-32P]dCTP. Binding reactions were set up as
described elsewhere (43) in a total volume of 25 l of binding buffer plus
5% glycerol, 1 mM dithiothreitol, and 0.25 ng of 32P-labeled oligonucleo-
tides. 12 g of crude nuclear extracts isolated from human cell lines
were used, and the binding reaction was carried out in the presence of
1 g of the nonspecific competitor poly(dIdC)poly(dIdC) (43). After 20
min of binding at room temperature, the samples were electrophoresed
at constant voltage (200 V) under low ionic strength conditions (0.25
TBE buffer  22 mM Tris borate, 0.4 mM EDTA) on 6% polyacrylamide
gels. Gels were dried and subjected to standard autoradiographic pro-
cedures (43). In competition experiments, the competitor molecules
carrying HIV-1 Sp1 binding sites (DNA/DNA, PNA/PNA, DNA/PNA,
PDP/PDP, and DNA/PDP) were preincubated for 20 min with nuclear
extracts, before the addition of labeled target DNA. Nuclear extracts
were prepared according to Dignam et al. (42). The nucleotide se-
quences of competitor double-stranded target DNAs used as controls
were 5-TAA TAT GTA AAA ACA TT-3 (sense strand, NF-IL2A), 5-
CAC TTG ATA ACA GAA AGT GAT AAC TCT-3 (sense strand, GATA-
1), and 5-CAT GTT ATG CAT ATT CCT GTA AGT G-3 (sense strand,
STAT-1).
Cell Lines and Culture Conditions—Human erythroleukemia
K562(S) cells (44) were cultured in a humidified atmosphere at 5% CO2
in RPMI 1640 (Flow Laboratories) supplemented with 10% fetal bovine
serum (CELBIO), 50 units/ml penicillin, and 50 g/ml streptomycin (45,
46). Cell growth was studied by determining the cell number/ml after
different days of in vitro cell culture (46). Stock solutions of ara-C (100
M) were stored at 20 °C in the dark and diluted immediately before
use. Treatment with the indicated concentrations of DNA- and PNA-
based molecules was carried out by adding the appropriate concentra-
tions of the compounds at the beginning of the experiment (cells were
usually seeded at 30,000 cells/ml). The medium was not changed during
the induction period. K562 cells containing heme or hemoglobin were
detected by specific reaction with a benzidine/hydrogen peroxide solu-
tion as reported elsewhere (45, 46). The final concentration of benzidine
was 0.2% in 5 M glacial acetic acid, 10% H2O2 (45, 46).
Stability of Decoy Molecules—The stability of decoy molecules was
evaluated after incubation of DNA and PNA-DNA-PNA-based decoys
with 3 3 5-exonuclease III, 5 3 3--exonuclease, and DNase I.
ExoIII, -exonuclease, and DNase I were purchased from MBI Fermen-
tas (ExoIII and -exonucleases) and Promega Corp., Madison, WI
(DNase I). In addition, serum (fetal calf serum, Eurobio, 30 g/liter of
protein concentration) was also employed. After incubation with in-
creasing amounts of the enzymes (for 10 min in the case of ExoIII, for
30 min in the case of -exonuclease and DNase I), the decoy molecules
were layered on the top of a 2% agarose gel and detected by ethidium
bromide staining. Disappearance of the decoy molecule was considered
as an evidence of degradation by the employed enzymes. Results were
presented as percentage of recovery with respect to control untreated
reaction mixtures.
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Liposome Preparation—Egg phosphatidyl choline was purchased
from Lipid Products (Surrey, England). Tetralysine cationic lipids,
tetralysine-cholesterol (Lys4-Chol), and tetralysine-palmitate (Lys4-
Palm) were a generous gift of Prof. M. Marastoni (Department of Phar-
maceutical Sciences, University of Ferrara, Ferrara, Italy). Positively
charged liposomes were produced by a protocol based on reverse phase
evaporation followed by extrusion of the liposome suspension through
polycarbonate filters with homogeneous pore size. Liposomes were sub-
jected to one extrusion cycle through two stacked 400-nm pore size
filters followed by three extrusion cycles through two stacked 200-nm
pore size membranes in order to obtain unilamellar liposomes with a
homogeneous size distribution. Different cationic detergents were al-
ternatively used for the production of the liposomes, namely Lys4-Chol
and Lys4-Palm (47). The resulting liposomal formulations were named
as follows: lipo-Lys4-Chol and lipo-Lys4-Palm. The morphological and
dimensional analysis of the produced liposomes was performed by
freeze-fracture electron microscopy technique and photo correlation
spectroscopy (Zetasizer, Malvern, UK). The freeze-fracture electron mi-
crographs (47, 48) confirmed that the extruded liposomal suspension
was mainly constituted by unilamellar vesicles. Photon correlation
spectroscopy studies demonstrated that the extruded vesicles present a
narrow size distribution with an average diameter reflecting the pore
size of the employed membrane.
For analysis of protective effects, 32P-labeled DNA/DNA and DNA/
PNA hybrids were incubated with increasing amounts (2–25 g/reac-
tion) of lipo-Lys4-Chol and lipo-Lys4-Palm for 30 min at room temper-
ature. A further overnight incubation period was then performed in the
absence or in the presence of a 25-l reaction of serum, and 32P-labeled
material was phenol-extracted, ethanol-precipitated, and analyzed by
polyacrylamide gel electrophoresis and autoradiography.
RESULTS
Design of Synthetic Oligonucleotides, PNAs and PNA-DNA
Chimeras—The design of the Sp1 oligonucleotides, PNA, and
PNA-DNA-PNA chimeras was conducted, taking into account
possible solubility and self-annealing problems related to the
chemical properties of the molecules. Indeed, it has been re-
ported that PNAs could exhibit low solubility at high GC/
AT ratios (29, 30). In addition, oligonucleotides mimicking
Sp1 binding sites but exhibiting intramolecular self-comple-
mentary stretches should not be considered in order to avoid
self-hybridization of the molecules to be used for production of
a double-stranded decoy. For these reasons, we decided to
synthesize oligonucleotides, PNAs, and PNA-DNA-PNA chime-
ras mimicking a genomic region present within the HIV-1 LTR
and containing Sp1 binding sites exhibiting a GC/AT ratio
lower than Sp1 binding sites present in the promoter sequences
of most eukaryotic genes (Table I and data not shown).
The nucleotide sequences of the employed HIV-1 Sp1 oligo-
nucleotides are shown in Table I, together with the other Sp1
oligonucleotides, PNAs, and PNA-DNA chimeras employed in
this study. We synthesized two oligonucleotides, HIV-Sp1 (14-
mer) and HIV-Sp1-L (19-mer), whose sequences are identical to
HIV-Sp1(PNA) and HIV-Sp1(PDP), respectively. The PNA-
DNA-PNA chimera carries a DNA sequence, identical to HIV-
Sp1 DNA and HIV-Sp1(PNA), flanked by two PNA stretches at
both ends. Since we wanted to define the decoy activity of these
molecules in the double-stranded configuration, the comple-
mentary oligonucleotides, PNAs, and PNA-DNA chimeras were
also synthesized. Two classes of oligonucleotides were also pro-
duced: (a) three DNA molecules carrying the Sp1 binding sites
present in the promoters of the human urokinase-type plas-
minogen activator receptor (uPAR-Sp1), -globin (-glob-Sp1),
and -globin (-glob-Sp1) genes and (b) additional oligonucleo-
tides carrying unrelated binding sites for NF-IL2A, STAT-1,
and GATA-1 transcription factor proteins. The sequences of
these oligonucleotides are shown in Table I or stated under
“Materials and Methods.”
Fig. 1 shows all the decoy molecules analyzed in our study.
The DNA/DNA, PNA/PNA, and PDP/PDP hybrids were pro-
duced after annealing of the complementary DNA, PNA, and
PNA-DNA-PNA molecules. DNA/PNA and PNA/DNA hybrids
were produced after annealing of HIV-Sp1 14-mer DNA and
HIV-Sp1(PNA). DNA/PDP and PDP/DNA hybrids were pro-
duced after annealing of the HIV-Sp1-L 19-mer DNA and
HIV-Sp1(PDP).
The Double-stranded PNA/DNA, DNA/PNA, and PNA/PNA
Hybrids Carrying Sp1 Binding Sites Are Unable to Inhibit the
Interactions between Sp1 Nuclear Factors and Target DNA/
DNA Molecules—When 12 g of crude nuclear extracts from
human leukemic K562 cells were incubated for 20 min in the
presence of the cold double-stranded 14- and 19-bp Sp1 DNA/
DNA hybrids, a concentration-dependent inhibition of interac-
tions between 32P-labeled Sp1 14-mer and nuclear factors was
observed (Fig. 2A). As expected, the longer double-stranded
HIV-Sp1 oligonucleotide displayed higher decoy efficiency with
respect to the 14-mer oligonucleotide. 50% inhibition of Sp1-
DNA interactions was obtained with 25 ng of the 14-mer oligo-
nucleotide and 6 ng of the 19-mer oligonucleotide (Fig. 2A,
lower part of the panel). The experiments shown in Fig. 2B, left
side of the panel, and Fig. 2C, lower side of the panel, clearly
indicate that DNA/PNA, PNA/DNA, or PNA/PNA HIV-Sp1
molecules are unable, even when added at 100 ng/reaction, to
inhibit the interactions between 32P-labeled Sp1 14-mer and
nuclear factors.
The Double-stranded DNA/PDP, PDP/DNA, and PDP/PDP
Molecules Carrying PNA-DNA-PNA Chimeras Mimicking Sp1
Binding Sites Efficiently Inhibit the Interactions between Sp1
Nuclear Factors and Target DNA/DNA Molecules—The effects
of putative decoy molecules based on PNA-DNA chimeras were
at first determined on the molecular interactions between 32P-
labeled Sp1 14-mer and nuclear factors (Fig. 2, B and C);
subsequently, their effects were also assayed using the 32P-
TABLE I
Synthetic oligonucleotides, PNA, and PNA-DNA chimeras
PNA stretches are underlined.
Gene/genome Entry Sequence Length
Oligonucleotides HIV-1 HIV-Sp1 5-TGAGGCGTGGCCT-3 14-mer
HIV-Sp1c 5-AGGCCACGCCTCA-3 14-mer
HIV-Sp1-L 5-CAGTGAGGCGTGGCCAGGG-3 19-mer
HIV-Sp1-Lc 5-CCCTGGCCACGCCTCACTG-3 19-mer
uPA receptor uPAR-Sp1 5-CCAGCCGGCCGCGCCCCGGGAAGGGA-3 26-mer
uPAR-Sp1c 5-TCCCTTCCCGGGGCGCGGCCGGCTGG-3 26-mer
-globin -glob-Sp1 5-CTAAACTCCACCCATGGGTT-3 20-mer
-glob-Sp1c 5-AACCCATGGGTGGAGTTTAG-3 20-mer
	-globin 	-glob-Sp1 5-GGACCTGACTCCACCCCTGAGG-3 22-mer
	-glob-Sp1c 5-CCTCAGGGGTGGAGTCAGGTCC-3 22-mer
PNA HIV-1 HIV-PNA-Sp1 NH2-TGA GG CGT GGC CT-Ac 14-mer
HIV-PNA-Sp1c NH2-AGG CCA CGC CTC A-Ac 14-mer
PNA-DNA chimeras HIV-1 HIV-PDP-Sp1 NH2-CAGTGAGGCGTGGCCAGGG-gly 19-mer
HIV-PDP-Sp1c NH2-CCCTGGCCACGCCTCACTG-gly 19-mer
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labeled Sp1 19-mer (Fig. 3). The results obtained clearly indi-
cate that DNA/PDP and PDP/DNA hybrids are efficient decoys
(in particular, see Fig. 2C). PDP/PDP molecules are also able to
suppress the interactions between 32P-labeled Sp1 14-mer and
nuclear factors, but when added to the binding reaction at a
concentration of 25 ng/reaction. These effects were reproduc-
ibly obtained also using the 32P-labeled Sp1 19-mer. In this
case, the binding of nuclear factors to the target DNA origi-
nates three retarded bands (Fig. 3, arrows). We first performed
control experiments demonstrating the decoy effects of the
double-stranded HIV-Sp1 19-mer DNA/DNA (Fig. 3A); then, we
demonstrated that NF-IL2A and GATA-1 DNA/DNA hybrids
had no inhibitory effects on the binding of nuclear factors to the
32P-labeled Sp1 19-mer (Fig. 3B). Fig. 3C demonstrates that
DNA/PDP, PDP/DNA, and PDP/PDP hybrids are able to effi-
ciently inhibit the interactions between the 32P-labeled Sp1
19-mer and nuclear factors. Fig. 3C (right side of the panel)
shows that DNA/PNA, PNA/DNA, and PNA/PNA hybrids car-
rying Sp1 binding sites do not exhibit any decoy activity even
when added at 200 ng/reaction. Finally, HIV-Sp1 PDP/DNA
and PDP/PDP hybrids exhibit low ability to inhibit the gener-
ation of the fast mobility band. This was reproducibly obtained
in independent experiments and tentatively explained by a
different affinity of PNA-DNA-based decoy molecules for dif-
ferent proteins (or protein complexes) belonging to the Sp1
family.
The Double-stranded DNA/PDP, PDP/DNA, and PDP/PDP
Molecules Carrying PNA-DNA-PNA Chimeras Mimicking
HIV-1 Sp1 Binding Sites Do Not Inhibit the Interactions be-
tween STAT-1, NF-IL2A, and GATA-1 Transcription Factors to
the Relative Target DNA-DNA Sequences—The results re-
ported in Fig. 4, which were performed using 32P-end-labeled
STAT-1, NF-IL2A, and GATA-1 DNA-DNA target molecules
and nuclear factors isolated from the K562 cell line, firmly
establish that the effects of PNA-DNA chimera-based decoy
molecules are sequence-specific. In fact, although STAT-1, NF-
IL2A, and GATA-1 cold oligomers suppress the binding of nu-
clear factors to the relative 32P-end-labeled DNA/DNA target
molecules, no inhibitory activity was determined by addition of
double-stranded PDP/DNA, DNA/PDP, and PDP/PDP chimera
mimicking the HIV-1 Sp1 binding sites.
Binding of Nuclear Factors to 32P-labeled DNA/PDP, PDP/
DNA, and PDP/PDP Chimeras—To directly confirm that PNA-
DNA chimera-based molecules are recognized by Sp1 factors,
we carried out another set of experiments. DNA strands were
labeled with [-32P]ATP before annealing to the PNA-DNA-
PNA chimera or PNA-relative counterparts (Fig. 5). This al-
lows the generation of 32P-labeled Sp1 DNA/PNA, PNA/DNA,
DNA/PDP, and PDP/DNA molecules. In addition, PDP/PDP
molecules were labeled by nick translation reaction, using low
amounts of DNase I, as described under “Materials and Meth-
ods” and reported elsewhere (56). When these PNA and PDP-
based 32P-labeled hybrids were added to 12 g of nuclear ex-
tracts from K562 cells, only DNA/PDP and PDP/DNA
molecules generated a clearly detectable retarded band (Fig.
5A). The retarded band generated by PDP/PDP hybrids is
barely detectable (Fig. 5A, right panel), as expected in consid-
FIG. 1. Structure and sequences of the decoy molecules em-
ployed. DNA stretches are in green, PNA stretches are in dark blue.
FIG. 2. Effects of DNA-, PNA-, and PDP-based hybrids on mo-
lecular interactions between nuclear proteins and 32P-labeled
HIV-1 Sp1 14-mer DNA/DNA target molecules. 12 g of K562
nuclear extracts were incubated for 20 min in binding buffer in the
absence () or in the presence of the indicated amounts of decoy mol-
ecules. After this incubation period, a further 20-min incubation step
was performed in the presence of 32P-labeled HIV-1 Sp1 14-mer DNA/
DNA target molecules. Protein/DNA complexes were separated by poly-
acrylamide gel electrophoresis, and autoradiography was performed.
Arrows indicate protein/DNA complexes. * indicates the free 32P-labeled
Sp1 mer.
Binding of Sp1 Proteins to PNA-DNA Chimeras 7503
eration of the low specific activity of these 32P-labeled mole-
cules (56). On the contrary, Sp1 DNA/PNA and PNA/DNA
hybrids were unable to generate retarded bands, as shown in
Fig. 5B. In this experimental approach, Sp1 PNA/PNA hybrids
were not considered due to the difficulty of obtaining radioac-
tive molecules. The data shown in Fig. 5 confirm on the one
hand that Sp1 PNA/DNA hybrids are not efficiently recognized
by Sp1 nuclear factors, whereas PDP-based hybrids are recog-
nized by these nuclear proteins. Despite the slightly different
retarded patterns obtained, the data shown in Fig. 5A support
the hypothesis that the decoy activity of Sp1 PDP-based hy-
brids (Figs. 2 and 3) is due to the ability of these molecules to
interact with transcription factors belonging to the Sp1 family.
The Double-stranded DNA/PDP, PDP/DNA, and PDP/PDP
Molecules Carrying PNA-DNA-PNA Chimeras Mimicking the
HIV-1 Sp1 Binding Sites Inhibit the Interactions between Nu-
clear Factors and Sp1 Binding Sites Present within the Pro-
moter of Genes Coding -Globin, -Globin, and uPAR—The
experiment reported in Fig. 6 (A–C) was performed using 32P-
end-labeled -globin Sp1 DNA-DNA target molecules and nu-
clear factors isolated from K562 cells. The results obtained
firmly establish that DNA/PDP, PDP/DNA, and PDP/PDP
HIV-Sp1 molecules are able to inhibit the binding of nuclear
factors to 32P-end-labeled -globin Sp1 DNA-DNA target mol-
ecules when added at high concentrations (50 ng/reaction; Fig.
6C, left side of the panel).
The same extent of inhibition was reached using 6 and 12 ng
of -globin Sp1 DNA/DNA and HIV-Sp1 DNA/DNA hybrids,
respectively (Fig. 6, A and B). Inhibitory effects of DNA/PDP,
PDP/DNA, and PDP/PDP HIV-Sp1 molecules were also found
on the binding of nuclear factors to 32P-end-labeled -globin
(Fig. 6D) and uPAR (Fig. 6E) Sp1 DNA-DNA target molecules.
These data demonstrate that the HIV-Sp1 decoy is able to
inhibit the binding of Sp1 factors to other promoter elements
carrying Sp1-like binding sites.
Ex Vivo Effects of PDP-based Decoy Hybrids: Inhibition of
ara-C-induced Erythroid Differentiation of K562 Cells—The
finding that DNA/PDP, PDP/DNA, and PDP/PDP HIV-Sp1
molecules are able to inhibit the binding of nuclear factors to
32P-end-labeled -globin and -globin Sp1 DNA-DNA target
molecules prompted us to determine their effects on the human
leukemic K562 cells. This cell line does not produce large
amounts of hemoglobin (Fig. 7A) but, after treatment for 5–7
days with a variety of chemical inducers, among which were
5-azacytidine (45), mithramycin (43), tallimustine (44), and
cytosine arabinoside (ara-C) (44), they undergo erythroid dif-
ferentiation, becoming positive to the benzidine stain (benzi-
dine-positive cells as shown in Fig. 7B). Erythroid differentia-
tion of K562 cells is associated with accumulation of Hb
Portland (
22) and Hb Gower 1 (
22) (43). Therefore, activa-
tion of both -globin and -globin genes is operated in eryth-
roid-induced K562 cells, as also determined and elsewhere
verified by Northern blotting and quantitative reverse tran-
scription-PCR analysis (44). Interestingly, if ara-C-treated
K562 are cultured in the presence of HIV-Sp1 DNA/DNA mol-
ecules, erythroid differentiation is inhibited (Fig. 7C). In con-
trast, unrelated double-stranded oligonucleotides are unable to
exert this inhibitory effect (Fig. 7C). The finding that Sp1
double-stranded oligonucleotides are able to inhibit erythroid
differentiation of K562 cells is in agreement with a number of
reports pointing out that Sp1 transcription factor could be
involved in transcriptional regulation of the expression of
erythroid-specific genes, including the human globin genes
(49–54).
Therefore, we determined the activity of HIV-Sp1 DNA/PDP,
PDP/DNA, and PDP/PDP molecules on ara-C-treated K562
cells and compared this activity with that of HIV-Sp1 DNA/
DNA molecules. Cells were treated for 6 days in the presence or
absence of the indicated concentration of Sp1 decoy molecules,
and the proportion of benzidine-positive cells was determined.
The results obtained are shown in Fig. 7D and demonstrate
that all PDP-based Sp1 decoys are able to reduce the ara-C-
induced increase of benzidine-positive cells. Among PDP-based
decoy molecules, the most active ones on the inhibition of
erythroid differentiation were found to be DNA/PDP and PDP/
DNA. On the contrary, only slight inhibition was found using
PDP/PDP decoy molecules. Control experiments demonstrated
that unrelated DNA/DNA molecules were almost uneffective in
inhibiting ara-C-mediated increase of the proportion of benzi-
dine-positive cells (data not shown and Fig. 7D). These exper-
iments suggest that PNA-DNA chimera-based decoy molecules
for Sp1 nuclear factors are active on ex vivo experimental cell
systems, their efficiency being very similar to that of Sp1 DNA/
DNA decoy molecules, at least in the case of DNA/PDP and
PDP/DNA hybrids.
Stability of the Decoy Molecules Based on PNA-DNA-PNA
Chimeras—The results of the experiments shown in Figs. 2, 3,
and 7 suggest that double-stranded biomolecules based on
PNA-DNA chimeras might be considered efficient decoy mole-
cules. To propose these biomolecules for gene therapy, however,
two points should be, in our opinion, addressed: stability of the
decoy molecules in serum and possible delivery with commonly
used vectors, such as liposomes.
To determine the stability of the decoy molecules based on
FIG. 3. Effects of DNA-, PNA-, and PDP-based hybrids on mo-
lecular interactions between nuclear proteins and 32P-labeled
HIV-1 Sp1 19-mer DNA/DNA target molecules. 12 g of K562
nuclear extracts were incubated for 20 min in binding buffer in the
absence () or in the presence of the indicated amounts of decoy mol-
ecules. After this incubation period, a further 20-min incubation step
was performed in the presence of 32P-labeled HIV-1 Sp1 19-mer DNA/
DNA target molecules. Protein/DNA complexes were separated by poly-
acrylamide gel electrophoresis, and autoradiography was performed.
Arrows indicate protein/DNA complexes. * indicates the free 32P-labeled
Sp1 mer. Control DNA/DNA competitors carrying binding sites for
GATA-1 and NF-IL2A were used, as indicated.
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PNA-DNA-PNA chimeras mimicking the Sp1 binding sites,
unlabelled PDP/PDP molecules or 32P-end-labeled DNA/PDP
and PDP/DNA HIV-Sp1 hybrid molecules were incubated (a)
with increasing amounts of 3 3 5-exonuclease (Fig. 8, A and
B) and (b) with serum (Fig. 8C). After incubations, the decoy
molecules were isolated, layered on the top of a polyacrylamide
(the 32P-labeled decoy molecules) or an agarose gel (the unla-
belled decoy molecules), and electrophoresed, and autoradiog-
raphy was performed in the case of DNA/PDP or DNA/DNA
molecules (Fig. 8A). In the case of PDP/PDP hybrids (Fig. 8B)
or when serum was employed (Fig. 8C), gels were stained with
ethidium bromide. This was necessary due to the 5-phospha-
tase activity present in serum, leading to a rapid removal of
5-32P (data not shown). Disappearance of the 32P-end-labeled
or ethidium bromide-stained bands indicates that degradation
of the decoy molecules has occurred. The observed stabilities of
PDP/PDP hybrids or DNA/PDP molecules were compared with
those of DNA/DNA decoy molecules.
Fig. 8 clearly demonstrates that Sp1 PDP/PDP decoy mole-
cules are resistant to ExoIII 3 3 5-exonuclease (Fig. 8B),
unlike the corresponding DNA/DNA hybrid. PDP/PDP chime-
ras are also resistant to serum (Fig. 8C, lower part of the
panel). When experiments were conducted using DNA/PDP
hybrids, the results obtained demonstrated that DNA/PDP hy-
brids exhibit a high level of resistance to both 3 3 5-exonu-
clease (Fig. 8A) and serum (Fig. 8C, middle part of the panel) as
compared with HIV-Sp1 DNA/DNA decoy oligonucleotides.
These results were consistently reproduced in three independ-
ent experiments; in addition, results similar to those obtained
with DNA/PDP molecules were also obtained using PDP/DNA
decoy hybrids (data not shown). Furthermore, DNA/PDP and
PDP/DNA molecules were consistently found more resistant
than DNA/DNA hybrids to 5 3 3-exonuclease and DNase I
and when exposed to cellular extracts.2 Taken together, these
data demonstrate that decoy molecules based on PNA-DNA-
PNA chimeras exhibit higher levels of resistance to nucleases
with respect to decoy molecules based on DNA/DNA hybrids.
Complexation of PDP-based Decoy Molecules to Cationic Li-
posomes—Different cationic detergents were used, namely
2 M. Borgatti, I. Lampronti, A. Romanelli, C. Pedone, M. Saviano, N.
Bianchi, C. Mischiati, and R. Gambari, manuscript in preparation.
FIG. 4. Effects of DNA/DNA, DNA/PDP, PDP/DNA, and PDP/PDP hybrids carrying Sp1 binding sites on the interaction between
crude nuclear extracts from human leukemic K562 cells and 32P-labeled STAT-1 (A), NF-IL2A (B), and GATA-1 (C) DNA-DNA target
molecules. 12 g of nuclear factors were incubated for 20 min in binding buffer in the absence () or in the presence of 100 ng of DNA/DNA,
DNA/PDP, PDP/DNA, and PDP/PDP molecules. After this incubation period, a further 20-min incubation step was performed in the presence of
32P-labeled DNA/DNA target molecules. Protein/DNA complexes were separated by polyacrylamide gel electrophoresis, and autoradiography was
performed. Arrows indicate protein/DNA complexes. * indicates the free 32P-labeled NF-IL2A, GATA-1 and STAT-1 mers. Control DNA/DNA
competitors carrying binding sites for STAT-1, NF-IL2A, and GATA-1 were used (100 ng) to verify the specificity of protein/DNA interactions
observed.
FIG. 5. Direct binding of nuclear factors to PDP- and PNA-
based hybrids. 32P-labeled Sp1 DNA/DNA (A and B), DNA/PDP (A),
PDP/PDP (A), DNA/PNA (B), and PNA/DNA (B) hybrids were incubated
for 20 min in binding buffer in the absence () or in the presence () of
12 g of nuclear extracts from K562 cells. Protein/DNA complexes were
separated by polyacrylamide gel electrophoresis, and autoradiography
was performed. Arrows indicate complexes between proteins and target
molecules.
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Lys4-Chol and Lys4-Palm, for the production of the liposomal
formulation (47, 48). The resulting liposomal formulations
were named as follows: lipo-Lys4-Chol and lipo-Lys4-Palm. The
complexation of PNA-DNA chimeras to liposomes was per-
formed just before the analysis, simply mixing the nucleic acid
to “preformed” cationic vesicles, resulting in a quantitative
association yield.
Fig. 9 (A and B) demonstrates that Lys4-Chol and Lys4-Palm
are able to complex to 32P-end-labeled HIV-Sp1 DNA/PDP and
PDP/DNA hybrids. This is demonstrated by the formation of
complexes (identified as bound material) unable to migrate into
the gels when high concentrations of liposomes were used (1–2
g/reaction). It should be noted that complexation of Sp1 DNA/
PDP and PDP/DNA to both Lys4-Palm and Lys4-Chol is similar
to complexation of Sp1 DNA/DNA hybrids. Both Lys4-Chol and
Lys4-Palm are also able to complex with PDP/PDP HIV-Sp1
(Fig. 9C). In this case, due to the difficulty in obtaining 32P-
labeled PDP/PDP chimeras (56), unlabelled PDP/PDP mole-
cules were used, and the gels were stained with ethidium
bromide. The data presented in Fig. 9 conclusively demonstrate
that Sp1 decoy molecules based on PNA-DNA chimeras can be
complexed to cationic liposomes.
These results are relevant for the delivery of PDP-based
decoys, as well as for a possible increase of their resistance to
nucleases. This could be particularly important for PDP/DNA
and DNA/PDP molecules. To determine whether liposome com-
plexation leads to an increase of resistance of PDP/DNA mole-
cules to degradation in serum, the experiment shown in Fig. 9D
was performed. Free or liposome-complexed 32P-end-labeled
DNA/PDP HIV-Sp1 hybrid molecules were incubated in the
presence of serum concentrations causing complete degrada-
tion of the PNA/DNA molecules (as shown in Fig. 8C, lane d).
The results obtained clearly suggest that complexation of
Sp1 DNA/PDP molecules to both Lys4-Chol and Lys4-Palm
liposomes leads to a protective effect against enzymatic
degradation.
DISCUSSION
The transcription factors belonging to the Sp1 superfamily
are of great importance for the control of expression of a variety
of genes. Members of this family of regulatory proteins bind
with varying affinities to sequences designated as “Sp1 sites”
(for instance GC and CACCC boxes), making up a transcrip-
tional network playing an important role in the fine-tuning of
gene expression. Sp1-dependent transcription can be growth-
regulated, and the activity, expression, and/or post-translational
modification of multiple family members is altered with cell
growth. Furthermore, Sp1 factors are involved in many growth-
related signal transduction pathways, apoptosis, and angiogene-
sis and, therefore, in several aspects of tumorigenesis (51).
With respect to gene therapy, the decoy approach against
Sp1 transcription factors has been proposed as a useful tool to
FIG. 6. Effects of DNA-, PNA-, and PDP-based hybrids on molecular interactions between nuclear proteins and 32P-labeled Sp1
binding sites present in the -globin (A–C), -globin (D), and uPAR (E) promoters. 12 g of K562 nuclear extracts were incubated for 20
min in binding buffer in the absence () or in the presence of the indicated amounts of decoy molecules. After this incubation period, a further
20-min incubation step was performed in the presence of 32P-labeled -glob-Sp1, -glob-Sp1, and uPAR target molecules. Protein/DNA complexes
were separated by polyacrylamide gel electrophoresis, and autoradiography was performed. Arrows indicate protein/DNA complexes. * indicates
the free 32P-labeled Sp1 mer. Control DNA/DNA competitor carrying binding sites for GATA-1 was used, as indicated.
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alter Sp1-dependent gene expression (3, 21, 25). This was
achieved by using synthetic ODNs carrying Sp1-specific cis
elements as decoy molecules.
In fact, Ishibashi et al. (3) demonstrated that Sp1 decoy
ODNs are able to inhibit the tumor necrosis factor--mediated
expression of vascular endothelial growth factor, transforming
growth factor 1, and tissue factor by cancer cells. In another
report, Verrecchia et al. (21) found that decoy Sp1-binding
oligonucleotides inhibited COL1A2 promoter activity both in
cultured fibroblasts and in vivo. Motojima et al. (22) demon-
strated that Sp1 decoys are able to inhibit angiotensin II-
induced expression of PAI-1 gene in mesangial cells. Finally,
Hata et al. (25) showed that treatment with Sp1 decoys reduced
expression of kinase domain receptor, a tyrosine kinase recep-
tor for vascular endothelial growth factor. This transcription-
ally regulated receptor is a critical mediator of endothelial cell
growth and vascular development. Unfortunately, synthetic
ODNs are not stable and, therefore, should be extensively
modified to be used in vivo or ex vivo (1–7).
In a recent study, we proposed PNAs as alternative reagents
in experiments aimed at the control of gene expression involv-
ing the decoy approach (20). In PNAs, the pseudopeptide back-
bone is composed of N-(2-aminoethyl)glycine units (27–30).
PNAs hybridize with high affinity to complementary sequences
of single-stranded RNA and DNA, forming Watson-Crick dou-
ble helices (27), and are resistant to both nucleases and pro-
teases (32). We demonstrated that NF-B p52 is able to bind to
both NF-B DNA/DNA and DNA/PNA hybrid, mimicking the
NF-B target sites present in the HIV-1 LTR. However, the
binding of the NF-B DNA-PNA to NF-B transcription factors
FIG. 7. Effects of DNA-, PNA-, and
PDP-based hybrids on ara-C-medi-
ated induction of erythroid differen-
tiation of K562 cells. A and B, benzidine
staining of uninduced (A) and ara-C-in-
duced K562 (B) cells. C, increase in the
proportion of benzidine-positive cells cul-
tured with 1 M ara-C in the absence
(closed symbols) or in the presence (open
symbols) of 5 g/ml HIV-1 Sp1 DNA/DNA
molecules. D, effects of DNA/DNA, DNA/
PDP, PDP/DNA, and PDP/PDP molecules
on increase of benzidine-positive cells af-
ter 6 days of cell culture in the presence of
5 g/ml decoy molecules. (), ara-C-
treated K562 cells.
FIG. 8. Stability of decoy molecules. A and B, experiments showing the effects of Exo III on DNA/DNA (A and B), DNA/PDP (A), and PDP/PDP
(B) decoy molecules. 250 ng of HIV-1 Sp1 PDP/PDP, DNA/PDP, and DNA/DNA decoys were incubated for 10 min in the absence (a) or in the
presence of 0.001 (b), 0.01 (c), 0.1 (d), 1 (e), 10 (f), and 100 (g) units of Exo III in a 20-l reaction mixture. After incubation, the decoy molecules
were layered on the top of a 20% polyacrylamide gel and detected by autoradiography (A) or on 2% agarose gels and detected by ethidium bromide
staining (B). C, differential effects of serum (a  no serum; b  3 l/reaction; c  12.5 l/reaction; d  25 l/reaction) on DNA (upper part of the
panel) and PNA-DNA-PNA (middle and lower parts of the panel)-based decoys. Incubations were conducted at 37 °C for 3 h in a 50-l reaction
mixture. After incubation, the decoy molecules were layered on the top of a 2% agarose gel and detected by ethidium bromide staining. DNA/DNA
and DNA/PDP hybrids were 32P-labeled in panel A. In panels B and C, unlabelled decoy molecules were used. Disappearance of the decoy molecules
was considered as an evidence of degradation by the employed enzymes.
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was found to exhibit low stability and, therefore, this reagent is
expected to be unsuitable for a decoy approach (20).
More recently, we determined whether PNA-DNA chimeras
mimicking NF-B binding sites are capable of stable interac-
tions with proteins belonging to the NF-B family (55). DNA-
PNA chimeras were originally proposed to improve the poor
cellular uptake and solubility of PNAs (30). More recently, they
were found to exhibit biological properties typical of DNA, such
as the ability to stimulate RNaseH activation and to act as
substrate for cellular enzymes (for instance, DNA polymerases)
(30). Molecular modeling was employed for the design of PNA-
DNA chimeras; prediction of molecular interactions between
chimeras and NF-B nuclear proteins were investigated by
molecular dynamics simulations, and interactions between
PNA-DNA chimeras and NF-B proteins were studied by gel
shifts. We found significant differences between the structure
of duplex NF-B PNA-DNA chimera and duplex NF-B DNA-
DNA (31). However, it was found that these differences do not
prevent the duplex PNA-DNA chimera from binding to NF-B
transcription factors, being able to suppress the molecular in-
teractions between HIV-1 LTR and p50, p52, and nuclear fac-
tors from B-lymphoid cells. Therefore, these results demon-
strate that the designed NF-B DNA-PNA chimeras could be
used for a decoy approach in gene therapy.
In the present report, our main focus was to determine
whether decoy molecules based on PNA and PNA-DNA chime-
ras are capable of stable interactions with Sp1 and, therefore,
could act as decoy reagents able to inhibit molecular interac-
tions between Sp1 and DNA. The results obtained firmly indi-
cate that Sp1-molecules based on PNA-DNA-PNA chimeras are
powerful decoy reagents (Figs. 2, 3, and 6). This effect is specific
since these decoys do not affect binding of NF-IL2A, GATA-1,
and STAT-1 to their binding elements.
A second conclusion to be drawn from the results of this
report is that PDP/DNA and DNA/PDP Sp1 decoy molecules
exhibit the ability to inhibit ara-C-induced erythroid differen-
tiation of human leukemia K562 cells to an extent similar to
that of Sp1 DNA/DNA decoys. This finding supports the hy-
pothesis of a biological activity of decoy molecules based on
PNA-DNA chimeras.
Our results are expected to have practical implications. The
finding that DNA-PNA chimeras stably interact with Sp1 tran-
scription factors encourages further experiments focused on
the possible use of these molecules for the development of
potential agents for a decoy approach in gene therapy. In this
respect, the finding that PDP-based decoy molecules are more
resistant than DNA/DNA hybrids to enzymatic degradation
(Fig. 8 and data not shown) appears to be of great interest.
Furthermore, their resistance can even be improved, and their
delivery could be facilitated after complexation with cationic
liposomes or microspheres (56) to which PDP/PDP chimeras
are able to bind by virtue of their internal DNA structure.
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